On June 12, 2017, the Supreme Court decided Amgen v. Sandoz, the landmark case about the meaning of the Biologics Price Competition and Innovation Act (BPCIA). First, the Supreme Court held that no federal injunction is...more
6/14/2017
/ Amgen ,
Amgen v Sandoz ,
Biosimilars ,
BPCIA ,
Injunctions ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Sandoz ,
SCOTUS